June 2024

When treating patients with graft-vs-host disease, pharmacists are often responsible for selecting treatment regimens while navigating other spheres of care.

Site-of-care considerations can pose challenges with these therapies.

Oncology pharmacists can help normalize and encourage SOGI data collection.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

Questions arise around equity and revenue challenges.

Fostering communication and shared terminology is key.

A pharmacist examines the intersection of medicine and humanity.

Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Incorporating ethical principles at all levels can ensure the best possible outcomes under difficult circumstances.

Strategies to advance sex and gender equality nationally and globally in oncology have been initiated in recent years.

Drug shortages, such as the shortages of cisplatin and carboplatin in 2023, have significantly affected oncology.